The 'reflation' sensation: Emerging markets poised to benefit from vaccine rollout and sustained global recovery

Macro scenarios set to work in sector's favour

clock
Nick Eisinger of Vanguard
Image:

Nick Eisinger of Vanguard

In the first part of the year, the vaccine rollout is supporting a robust economic recovery and global central banks continue to operate very loose monetary policy.

This scenario favours the emerging markets (EM) asset class, which is relatively well placed to benefit from the global 'reflation' trade. We are, however, mindful of the impact of higher US Treasury...

To continue reading this article...

Join Investment week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Emerging markets

Dominic Scriven OBE of Dragon Capital

Vietnam: the ESG investment case

Energy and digital transformation

Dominic Scriven
clock 13 May 2022 • 4 min read
Ritu Vohora of T. Rowe Price

From beverage manufacturers to luxury goods: How pricing power trumps inflation

Valuations matter more than before

Ritu Vohora
clock 12 May 2022 • 4 min read
Nick Smallwood is an EM debt portfolio manager & EM financials strategist at M&G

M&G: Is LatAm the place to be in 2022?

Outflows lighter than anticpated

Nick Smallwood
clock 10 May 2022 • 3 min read
Trustpilot